Health Technology

Third Wave Technologies is just fine with a recent Food and Drug Administration announcement on relabeling for the blood thinning drugs Coumadin and Wafarin, which have been linked to adverse drug reactions in emergency room settings. The Madison biotechnology company soon will provide an update...

Thanks to an error in the way it accounted for accounting for the revenue from contracts that contain both a license of software and related maintenance, Merge Healthcare again faces delisting from the NASDAQ Global Market. The company, which has delayed its financial report for...

These are heady days for the Wisconsin biotech industry, as the recent financial success of TomoTherapy and NimbleGen would attest, and the presence of Mentor Corp. at University Research Park would argue, according to Jim Leonhart, executive vice president of the Wisconsin Biotechnology and Medical...

Merge Healthcare has posponed the announcement of its financial resutls for the first six months of 2007. The Milwaukee-based company, a provider of medical imaging software, has been trying to recover from past financial reporting errors and the financial losses associated with them....

Jeff Williams, the new chief executive of Platypus Technologies, was brought back to Madison for his expertise in commercializing technology, and his new company will be giving him plenty of practice at bringing products to market. Platypus, which has developed nanotechnology-based research tools, is ready...

Technology convergence - namely IT and clinical medicine - will happen in ways that we cannot even imagine, according to MedTech Futures columnist Ogan Gurel. While we don't yet know the form, Dr. Gurel believes it's only a matter of time before this convergence is...

Tech transfer has several faces, including the medical informatics so prevalent in the Wisconsin economy, and two University of Wisconsin-Madison professors have developed software to add to that profile. Ray Vanderby and Hiro Kobayashi are pursuing a WARF patent for technology that images and quantifies...

Lucigen, a Madison company that develops gene cloning and protein expression technologies, has received a $250,000 grant from the National Institute of Mental Health. The grant will be used to fund the development of new methods of analyzing membrane proteins that could speed the development...

In a recently completed study, University of Wisconsin-Madison researchers played an integral role in providing new insights into amyotrophic lateral sclerosis or Lou Gehrig's Disease. Their study demonstrates the promise of cell-based therapies for diseases, including ALS, that have been difficult to manage for modern...

In his continuing series on early-stage companies, columnist Joe Boucher has covered many of the financing means for new businesses. For many ventures, both new and established ones, real estate is the most expensive asset to finance, but in this edition of Early Stage, Boucher...